Cantor Fitzgerald Issues Positive Forecast for GH Research (NASDAQ:GHRS) Stock Price

GH Research (NASDAQ:GHRS) had its price target raised by analysts at Cantor Fitzgerald from $35.00 to $40.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 30.55% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on GHRS. Citizens Jmp lowered their price target on GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, May 15th. HC Wainwright decreased their target price on GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Wells Fargo & Company started coverage on GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price target for the company. Needham & Company LLC lifted their price target on GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.11.

GH Research Stock Performance

GH Research stock opened at $30.64 on Friday. GH Research has a one year low of $11.32 and a one year high of $31.00. The business has a fifty day moving average of $25.57 and a two-hundred day moving average of $20.09. The company has a market cap of $2.10 billion, a P/E ratio of -33.30 and a beta of 1.29.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. Sell-side analysts predict that GH Research will post -1.46 EPS for the current year.

Institutional Investors Weigh In On GH Research

A number of large investors have recently bought and sold shares of the stock. Lynx1 Capital Management LP boosted its stake in shares of GH Research by 27.5% during the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after acquiring an additional 1,854,238 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in GH Research in the 4th quarter valued at about $22,860,000. Millennium Management LLC lifted its holdings in GH Research by 324.1% in the 3rd quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after purchasing an additional 659,957 shares in the last quarter. Troluce Capital Advisors LLC boosted its stake in shares of GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after purchasing an additional 617,260 shares during the last quarter. Finally, RTW Investments LP boosted its stake in shares of GH Research by 6.5% during the 4th quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock worth $75,359,000 after purchasing an additional 364,251 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.